Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824822 · ClinicalTrials.gov registry record
Genetic Markers of Cardiovascular Disease in Epilepsy
A clinical trial of Epilepsy and Seizures, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT02824822: Recruiting study of Epilepsy and Seizures, sponsored by Mayo Clinic.
NCT02824822 is a study of Epilepsy and Seizures that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 600 participants, below the 949-participant average among 160 other Epilepsy trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02824822, a study of Epilepsy and Seizures, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and sudden death related disorders in patients with epilepsy.
Primary Outcome
SUDEP-7 is a risk profiling tool, with a score ranging from 0-12. Generally, a score greater than or equal to 3 is considered high risk. The investigators will select participants with a family history of epilepsy, seizures, cardiac arrest, sudden death, drowning, syncope or arrhythmia, as this markedly increases genetic yield. Next Generation Whole-Exome Sequencing will be performed with a focus on known genes implicated in sudden unexpected death syndromes (channelopathies, cardiomyopathies a
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2016-05 |
| Est. Completion | 2031-12 |
What NCT02824822 shows while recruiting
NCT02824822 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 949-participant average among 160 other Epilepsy trials with a reported enrollment target (37% lower).
The record links to 5 conditions, with Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT02824822 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02824822 about?
NCT02824822 is a clinical study titled "Genetic Markers of Cardiovascular Disease in Epilepsy". Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to und...
What is the current status of trial NCT02824822?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2016-05. Estimated completion is 2031-12.
What conditions does trial NCT02824822 study?
This clinical trial studies the following conditions: Epilepsy, Seizures, Cardiomyopathies, Syncope, Channelopathy.
Who is sponsoring clinical trial NCT02824822?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02824822 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02824822's enrollment target sits among peer trials
600 11th of 160 higher than 150 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia